Rituximab (& biosimilar)

RED:

NICE TA195: Rituximab treatment of rheumatoid arthritis after failure of a TNF inhibitor. (August 2010)
NICE TA243: follicular lymphoma - recommended in combination for first line treatment of stage III-IV disease (decision date - February 2012)
NICE TA226: lymphoma (follicular non-Hodgkin's) - recommended as a possible treatment to maintain remission (decision date - July 2011)
NICE TA308: rituximab in combination with glucocorticoids for treating antineutrophil cytopasmic antibody - associated vasculitis (decision date - April 2014)
For immunobullous disease. NHSE commissioned (Decision date - August 2021)
For the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults. NHSE commissioned. (Decision date - February 2022)
SSC2433 – NHSE Clinical Commissioning policy for Rituximab in the management of Thrombotic Thrombocytopenic Purpura. (Decision date - November 2022)
SSC2440 – NHSE Clinical Commissioning policy for Rituximab for Idiopathic Membranous Nephropathy in adults. (Decision date - December 2022)

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)